×

Wall Street can't figure out how to value Valeant

Valeant Pharmaceuticals International business cards are displayed in the lobby of company's headquarters in Mississauga, Ontario, Canada.
Norm Betts | Bloomberg | Getty Images
Valeant Pharmaceuticals International business cards are displayed in the lobby of company's headquarters in Mississauga, Ontario, Canada.

Valeant shares are down almost 60 percent from early August highs and down 35 percent over the past 10 days on questions concerning its drug pricing business model, use of specialty pharmaceutical distribution through Philidor and allegations of channel stuffing by Citron Research.

Management held a conference call Monday morning for Wall Street as it sought to defend itself from the recent allegations.

Despite the 73-minute briefing, analysts were still left with more questions than answers about how to value Valeant's stock, which remains one of the top holdings among hedge funds.

Contact Investing

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    Get these newsletters delivered to your inbox, and more info about about our products and service. Privacy Policy.